Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cocrystal Pharma stock | $1.54

Own Cocrystal Pharma stock in just a few minutes.

Fact checked

Cocrystal Pharma, Inc is a biotechnology business based in the US. Cocrystal Pharma shares (COCP) are listed on the NASDAQ and all prices are listed in US Dollars. Cocrystal Pharma employs 11 staff and has a trailing 12-month revenue of around USD$1.9 million.

How to buy shares in Cocrystal Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cocrystal Pharma. Find the stock by name or ticker symbol: COCP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cocrystal Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.54, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cocrystal Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cocrystal Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cocrystal Pharma share price

Use our graph to track the performance of COCP stocks over time.

Cocrystal Pharma shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$1.54
52-week rangeUSD$0.45 - USD$2.48
50-day moving average USD$1.3518
200-day moving average USD$1.3399
Wall St. target priceUSD$4.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.467

Buy Cocrystal Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Bonds
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cocrystal Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cocrystal Pharma price performance over time

Historical closes compared with the close of $1.54 from 2020-12-09

1 week (2021-01-14) 0.65%
1 month (2020-12-22) 1.99%
3 months (2020-10-21) 75.00%
6 months (2020-07-21) -24.51%
1 year (2020-01-21) 105.88%
2 years (2019-01-18) -60.10%
3 years (2018-01-19) 719.58%
5 years (2016-01-21) 190.57%

Cocrystal Pharma financials

Revenue TTM USD$1.9 million
Gross profit TTM USD$2.6 million
Return on assets TTM -9.81%
Return on equity TTM -92.62%
Profit margin 0%
Book value $0.732
Market capitalisation USD$106.3 million

TTM: trailing 12 months

Shorting Cocrystal Pharma shares

There are currently 851,508 Cocrystal Pharma shares held short by investors – that's known as Cocrystal Pharma's "short interest". This figure is 53.3% down from 1.8 million last month.

There are a few different ways that this level of interest in shorting Cocrystal Pharma shares can be evaluated.

Cocrystal Pharma's "short interest ratio" (SIR)

Cocrystal Pharma's "short interest ratio" (SIR) is the quantity of Cocrystal Pharma shares currently shorted divided by the average quantity of Cocrystal Pharma shares traded daily (recently around 8.5 million). Cocrystal Pharma's SIR currently stands at 0.1. In other words for every 100,000 Cocrystal Pharma shares traded daily on the market, roughly 100 shares are currently held short.

However Cocrystal Pharma's short interest can also be evaluated against the total number of Cocrystal Pharma shares, or, against the total number of tradable Cocrystal Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cocrystal Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cocrystal Pharma shares in existence, roughly 10 shares are currently held short) or 0.016% of the tradable shares (for every 100,000 tradable Cocrystal Pharma shares, roughly 16 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cocrystal Pharma.

Find out more about how you can short Cocrystal Pharma stock.

Cocrystal Pharma share dividends

We're not expecting Cocrystal Pharma to pay a dividend over the next 12 months.

Have Cocrystal Pharma's shares ever split?

Cocrystal Pharma's shares were split on a 1:30 basis on 24 January 2018. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cocrystal Pharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Cocrystal Pharma shares which in turn could have impacted Cocrystal Pharma's share price.

Cocrystal Pharma share price volatility

Over the last 12 months, Cocrystal Pharma's shares have ranged in value from as little as $0.45 up to $2.48. A popular way to gauge a stock's volatility is its "beta".

COCP.US volatility(beta: 1.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cocrystal Pharma's is 1.1654. This would suggest that Cocrystal Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Cocrystal Pharma overview

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site